规格: | 98% |
分子量: | 784 |
包装 | 价格(元) |
500ug | 电议 |
1mg | 电议 |
5mg | 电议 |
Background:
Digoxin-d3is intended for use as an internal standard for the quantification of digoxin by GC- or LC-MS. Digoxin is a cardiac glycoside and metabolite of digitoxin that binds to and inhibits the Na+/K+-ATPase in cardiac tissues in an ATP- and Mg2+-dependent manner.1This inhibition results in loss of the transmembrane Na+gradient, which decreases activity of the Na+/Ca2+exchanger, increasing intracellular Ca2+levels, inotropy, and cardiac force.2It increases activity of mitochondrial ATPase and actomyosin ATPase in rat hearts, which is directly correlated with increased myofibrillar contractile strength.3In vivo, digoxin also decreases right atrial pressure and increases cardiac output in a canine model of congestive heart failure produced by pulmonary artery constriction.4Formulations containing digoxin have been used to treat atrial fibrillation.5
1.Matsui, H., and Schwartz, A.Mechanism of cardiac glycoside inhibition of the (Na+-K+)-dependent ATPase from cardiac tissueBiochim. Biophys. Acta.151(3)655-663(1968) 2.Neves, C.H., Tibana, R.A., Prestes, J., et al.Digoxin induces cardiac hypertrophy without negative effects on cardiac function and physical performance in trained normotensive ratsInt. J. Sports Med.38(4)263-269(2017) 3.Hamrick, M.E., and Fritz, P.J.Enzymatic adaptation: Molecular basis for cardiac glycoside action• 1. Increase in rat heart actomyosin and mitochondrial ATPase specific activities following digoxin injectionBiochem. Biophys. Res. Commun.22(5)540-546(1966) 4.Davis, J.O., Howell, D.S., and Hyatt, R.E.Effects of acute and chronic digoxin administration in dogs with right-sided congestive heart failure produced by pulmonary artery constrictionCirc. Res.3(3)259-263(1955) 5.Kotecha, D., Calvert, M., Deeks, J.J., et al.A review of rate control in atrial fibrillation, and the rationale and protocol for the RATE-AF trialBMJ Open7(7)e015099(2017)